Mebias Discovery

Mebias Discovery is a private, preclinical-stage biotech using a unique conformation-driven NMR platform to discover safer GPCR-targeting drugs. The company's lead asset, MEB-1170, is a mu-opioid receptor-targeted therapy for opioid use disorder (OUD) that has entered Phase 1 trials with support from the NIH's NIDA. Beyond this, Mebias is developing S1PR1 agonists for neuropathic pain and neuroinflammation, positioning itself at the intersection of addiction medicine and neurology. The company is backed by a mix of venture capital, angel investors, and significant non-dilutive grant funding from U.S. government agencies.

Proprietary membrane protein-NMR (Nuclear Magnetic Resonance) platform for conformation-driven discovery of biased ligands targeting G-protein coupled receptors (GPCRs).

The OUD treatment space is competitive with existing pharmacotherapies and several companies developing vaccines, monoclonal antibodies, and other novel mechanisms. The neuropathic pain field is also crowded, with many companies targeting ion channels, neurotrophins, and other inflammatory pathways. Mebias's differentiation hinges on its unique platform's ability to deliver superior, safer GPCR-targeted drugs.